|AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer|
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
|A history of prostate cancer treatment|
SR Denmeade, JT Isaacs
Nature Reviews Cancer 2 (5), 389-396, 2002
|Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer|
SR Denmeade, XS Lin, JT Isaacs
The Prostate 28 (4), 251-265, 1996
|Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer|
DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ...
Journal of Clinical Oncology 28 (9), 1496, 2010
|Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer|
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
|Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw|
AA Khan, GKB Sándor, E Dore, AD Morrison, M Alsahli, F Amin, E Peters, ...
The Journal of rheumatology 35 (7), 1391-1397, 2008
|Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer|
SR Denmeade, CM Jakobsen, S Janssen, SR Khan, ES Garrett, H Lilja, ...
Journal of the National Cancer Institute 95 (13), 990-1000, 2003
|Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.|
IB Joseph, JB Nelson, SR Denmeade, JT Isaacs
Clinical Cancer Research 3 (12), 2507-2511, 1997
|Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen|
SR Denmeade, W Lou, J Lövgren, J Malm, H Lilja, JT Isaacs
Cancer research 57 (21), 4924-4930, 1997
|Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with …|
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ...
Journal of Clinical Oncology 35 (19), 2149, 2017
|The SERCA pump as a therapeutic target: making a “smart bomb” for prostate cancer|
SR Denmeade, JT Isaacs
Cancer biology & therapy 4 (1), 21-29, 2005
|Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen|
SR Denmeade, A Nagy, J Gao, H Lilja, AV Schally, JT Isaacs
Cancer research 58 (12), 2537-2540, 1998
|Engineering a prostate-specific membrane antigen–activated tumor endothelial cell prodrug for cancer therapy|
SR Denmeade, AM Mhaka, DM Rosen, WN Brennen, S Dalrymple, I Dach, ...
Science translational medicine 4 (140), 140ra86-140ra86, 2012
|Knockin of mutant PIK3CA activates multiple oncogenic pathways|
JP Gustin, B Karakas, MB Weiss, AM Abukhdeir, J Lauring, JP Garay, ...
Proceedings of the National Academy of Sciences 106 (8), 2835-2840, 2009
|Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells|
CM Jakobsen, SR Denmeade, JT Isaacs, A Gady, CE Olsen, ...
Journal of medicinal chemistry 44 (26), 4696-4703, 2001
|Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy|
WN Brennen, JT Isaacs, SR Denmeade
Molecular cancer therapeutics 11 (2), 257-266, 2012
|Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models|
SR Denmeade, LJ Sokoll, S Dalrymple, DM Rosen, AM Gady, D Bruzek, ...
The Prostate 54 (4), 249-257, 2003
|Complete androgen blockade for prostate cancer: what went wrong?|
M Laufer, SR Denmeade, VJ SINIBALDI, MA Carducci, ...
The Journal of urology 164 (1), 3-9, 2000
|Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug|
WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade
Journal of the National Cancer Institute 104 (17), 1320-1334, 2012
|Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study|
MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ...
Science translational medicine 7 (269), 269ra2-269ra2, 2015